已收盘 02-06 16:00:00 美东时间
+0.400
+1.00%
今日重点评级关注:HC Wainwright & Co.:维持Rezolve AI"买入"评级,目标价从10美元升至12美元;HC Wainwright & Co.:维持Largo"买入"评级,目标价从2.9美元升至3.1美元
01-15 16:10
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22
Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:MRX) with a Overweight and lowers the price target from $50 to $49.
01-09 05:08
https://www.marex.com/news/2025/12/marex-launches-online-marketplace-transferable-clean-energy-tax-credits/
2025-12-17 22:45
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
2025-12-15 15:30
Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:MRX) with a Overweight and raises the price target from $43 to $50.
2025-12-13 04:22
Marex Group plc has acquired Winterflood Securities, enhancing its UK cash equities business, while planning to sell Winterflood Business Services (WBS) to Epiris Fund III. Marex will retain Winterflood's market making activities and brand, with WBS transferred to Epiris upon regulatory approval. The retained Winterflood business expects $75m annual revenue and a 20% profit margin. Ian Lowitt, Marex's CEO, highlighted the sale of WBS offsetting a...
2025-12-01 12:00
Marex Group plc (("Marex", NASDAQ:MRX), the diversified global financial services platform, has launched its structured products business in the United States to serve demand from registered investment advisors (RIAs),
2025-11-19 20:37
Marex Group has launched its structured products business in the U.S. to meet demand from RIAs, broker-dealers, and private banks seeking issuer and credit diversification.marex, a global non-bank issuer, brings expertise in structured products with over 20,000 issuances globally, offering faster product turnaround and transparent pricing.Structured investments are becoming core portfolio allocations, and Marex plans to provide a wide range of so...
2025-11-19 12:30
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17